Axsome Therapeutics (AXSM) – Research Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Axsome Therapeutics (NASDAQ: AXSM) in the last few weeks:

  • 1/14/2020 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at LADENBURG THALM/SH SH. They now have a $165.00 price target on the stock, up previously from $139.00.
  • 1/2/2020 – Axsome Therapeutics had its price target raised by analysts at SunTrust Banks, Inc. to $140.00. They now have a “buy” rating on the stock.
  • 12/30/2019 – Axsome Therapeutics had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $125.00 price target on the stock, up previously from $104.00.
  • 12/30/2019 – Axsome Therapeutics had its price target raised by analysts at BTIG Research to $97.00. They now have a “buy” rating on the stock.
  • 12/30/2019 – Axsome Therapeutics had its price target raised by analysts at LADENBURG THALM/SH SH from $139.00 to $165.00. They now have a “buy” rating on the stock.
  • 12/24/2019 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $200.00 price target on the stock, up previously from $170.00.
  • 12/17/2019 – Axsome Therapeutics had its price target raised by analysts at BTIG Research to $97.00. They now have a “positive” rating on the stock.
  • 12/17/2019 – Axsome Therapeutics had its price target raised by analysts at SunTrust Banks, Inc. to $100.00. They now have a “buy” rating on the stock.
  • 12/16/2019 – Axsome Therapeutics had its price target raised by analysts at Cantor Fitzgerald from $55.00 to $104.00. They now have an “overweight” rating on the stock.
  • 12/16/2019 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $125.00 price target on the stock.
  • 12/4/2019 – Axsome Therapeutics had its “positive” rating reaffirmed by analysts at SunTrust Banks, Inc.. They now have a $60.00 price target on the stock.
  • 12/4/2019 – Axsome Therapeutics had its “positive” rating reaffirmed by analysts at BTIG Research. They now have a $48.00 price target on the stock.
  • 12/4/2019 – Axsome Therapeutics had its price target raised by analysts at Guggenheim from $65.00 to $48.00.
  • 12/3/2019 – Axsome Therapeutics had its price target raised by analysts at Cantor Fitzgerald from $45.00 to $55.00. They now have an “overweight” rating on the stock.
  • 12/3/2019 – Axsome Therapeutics was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 11/26/2019 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $45.00 price target on the stock.
  • 11/20/2019 – Axsome Therapeutics was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 11/19/2019 – Axsome Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Axsome Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing novel therapies for the management of pain and other central nervous system disorders. Its product candidate portfolio consists of AXS-02 and AXS-05 which are in clinical trial stage. Axsome Therapeutics, Inc. is based in New York. “

Axsome Therapeutics stock opened at $88.30 on Tuesday. The company has a quick ratio of 2.39, a current ratio of 2.39 and a debt-to-equity ratio of 2.80. The company has a market capitalization of $3.06 billion, a PE ratio of -76.78 and a beta of 3.39. The firm has a fifty day simple moving average of $73.78 and a two-hundred day simple moving average of $37.10. Axsome Therapeutics Inc has a twelve month low of $7.01 and a twelve month high of $109.94.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.15). As a group, equities analysts expect that Axsome Therapeutics Inc will post -1.77 earnings per share for the current fiscal year.

Large investors have recently modified their holdings of the company. Bank of Montreal Can bought a new position in shares of Axsome Therapeutics during the second quarter valued at about $52,000. Schroder Investment Management Group purchased a new position in shares of Axsome Therapeutics during the second quarter valued at about $76,000. Ladenburg Thalmann Financial Services Inc. increased its position in shares of Axsome Therapeutics by 41.2% during the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,800 shares of the company’s stock valued at $124,000 after buying an additional 1,400 shares during the period. Metropolitan Life Insurance Co NY purchased a new position in shares of Axsome Therapeutics during the third quarter valued at about $171,000. Finally, Cambridge Investment Research Advisors Inc. purchased a new position in shares of Axsome Therapeutics during the second quarter valued at about $281,000. 54.64% of the stock is owned by hedge funds and other institutional investors.

Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder.

Further Reading: S&P/ASX 200 Index

Receive News & Ratings for Axsome Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.